


March 4, 2022
Hermitage hotel Prague

congressprague.cz/11th conference of central european
 hepatologic collaboration



Session 1

8:30 – 10:30 HCV and Covid	
Chairs: Petr Urbanek, Robert Flisiak	
HCV Clinical Practice Guidelines: The Course towards Desired Goal Urbanek P. (Czech Republic)	25 min.
HCV elimination in Central Europe with particular emphasis on microelimination in prisons Flisiak R. (Poland) Zarębska-Michaluk D., Ciupkeviciene E., Drazilova S., Frankova S., Grgurevic I., Hunyady B., Jarcuska P., Kupčinskas L., Makara M., Saulite-Vanaga G., Simonova M., Sperl J., Tolmane I., Vince A.	15 min.
New results of the Hungarian adverse childhood experiences study Makara M. (Hungary)	15 min.
Can we eliminate hepatitis B in Slovakia? Jarcuska P. (Slovakia)	25 min.
Pangenotypic and genotype-specific antivirals in the treatment of HCV Genotype 4 infected patients with HCV mono-infection and HIV/HCV coinfection Zarębska-Michaluk D. (Poland) Jaroszewicz J., Parfieniuk-Kowerda A., Pawłowska M., Janczewska E., Berak H., Janocha-Litwin J., Klapaczyński J., Tomasiewicz K., Piekarska A., Krygier R., Citko J., Tronina O., Dobrowolska K., Flisiak R.	15 min.
Liver injury in patients with covid-19 with liver disease and without underlying liver diseases Pazgan-Simon M. (Poland) Serafińska S., Kukla M., Kucharska M., Zuwała-Jagiełło J., Buczyńska I., Zielińska K., Simon K.	15 min.
10:30 – 11:00 Coffee Break	

Session 2

11:00 – 12:30 HCV and Liver Tumours

Chairs: Peter Jarcuska, Mihaly Makara

Safety and efficacy of DAA-therapy in patients with active malignancy Blaszowska M., (Poland) Jaroszewicz J.	15 min.
Hepatitis C viraemic donors in solid organ transplantation Frankova S. (Czech Republic)	20 min.
Steatosis after clearance of HCV infection and inflammatory response Tomasiewicz K. (Poland)	15 min.
Obesity after clearance of HCV infection Pitova V. (Czech Republic) Frankova S., Sperl J.	10 min.
Prognostic factors of hepatocellular cancer - analysis of Slovak cohort Drazilova S. (Slovakia)	15 min.
Neuroendocrine tumours and liver transplantation Filipec-Kanizaj T. (Croatia)	15 min.

12:30 – 13:45 Lunch

Session 3

13:45 – 15:30 Liver Cirrhosis and Rare Liver Diseases

Chairs: Radan Bruha, Ivica Grgurevic

Wilson's disease - diagnosis and treatment Bruha R. (Czech Republik)	25 min.
Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography Grgurevic I. (Croatia)	15 min.
Time-to a tertiary care and mortality of acutely decompensated cirrhosis Skladany, L. (Slovakia) Zilincanova, D., Adamcova Selcanova, S.	15 min.
Predictive value of sarcopenia and myosteatosi s in cirrhotic patients Trunecka P. (Czech Republik) Kyselova D., Mikova I.	20 min.
Use of CAP and LSM in detection of liver steatosis after liver Transplantation Mikolasevic I. (Croatia)	15 min.

Does HVPG predict response to FMT in severe alcoholic hepatitis? 15 min.
Bystrianska N. (Slovakia)
Skladany L.

15:30 – 16:00 Coffee Break

Session 4

16:00 – 17:30 Rare Liver Diseases

Chairs: Pavel Strnad, Jan Sperl

Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder 25 min.
Strnad P. (Germany)

Autoimmune hepatitis - Challenges of diagnostic and treatment 25 min.
Papp M. (Hungary)

New approaches in treatment of severe unconjugated hyperbilirubinemia 25 min.
Vitek L. (Czech Republik)